Key result
Prevail DCB trial evaluates 12-month target lesion failure in ISR and de novo small vessel disease.
Why the study?
In-stent restenosis remains the leading cause of PCI failure, particularly in small caliber coronary arteries where restenosis is common, making drug-coated balloons an attractive alternative.
Does the Prevail drug-coated balloon improve target lesion failure in patients with in-stent restenosis and de novo small vessel disease?
Does the Prevail drug-coated balloon improve target lesion failure in patients with in-stent restenosis and de novo small vessel disease?
The Prevail Global study will evaluate the safety and efficacy of the Prevail drug-coated balloon for the treatment of in-stent restenosis and de novo small vessel lesions.
Answers are grounded in this paper and cite their sources.
Evaluation of Prevail DCB for TLF in ISR and small vessels leaves open its comparative efficacy; randomized trials needed before adoption.
BACKGROUND AND RATIONALE: In-stent restenosis (ISR) remains the leading cause of treatment failure following percutaneous coronary intervention (PCI) with contemporary drug-eluting stents. Especially in small caliber coronary arteries, restenosis is common following PCI and represents a treatment challenge. Drug-coated balloons (DCB) are an attractive alternative to stents for treatment of both ISR and small vessel disease. The safety and efficacy of the Prevail DCB will be assessed for (1) the treatment of ISR and (2) de novo lesions in small vessels. TRIAL DESIGN: , Boston Scientific Corporation, Natick MA), and (2) patients with de novo small vessel disease undergoing PCI with the Prevail DCB as part of a single-arm study compared with a historical control. The primary endpoint is target lesion failure, defined as a composite of cardiac death, target vessel myocardial infarction, or clinically-driven target lesion revascularization at 12 months post procedure. Patient follow-up is planned for 1 month, 6 months, and yearly through 5 years. Enrollment is expected to start in early 2025. CONCLUSIONS: The Prevail Global study will directly assess the safety and efficacy of the Prevail DCB for the treatment of ISR and de novo small vessel lesions. TRIAL REGISTRATION: Prevail Global, NCT06535854, is registered at https://clinicaltrials.gov/study/NCT06535854.
No takes yet. Share an insight, caveat, or question.
Kandzari et al. (2025) studied this question. The Prevail drug-coated balloon will be evaluated for 12-month target lesion failure in patients with in-stent restenosis and de novo small vessel disease.
Synapse has enriched 10 related papers. Consider them for comparative context: